Journal of the American College of Cardiology Vol. 34, No. 1, by the American College of Cardiology ISSN /99/$20.
|
|
- Andrew Matthew Wheeler
- 5 years ago
- Views:
Transcription
1 Journal of the American College of Cardiology Vol. 34, No. 1, by the American College of Cardiology ISSN /99/$20.00 Published by Elsevier Science Inc. PII S (99) Effect of Aspirin and Ifetroban on Skeletal Muscle Blood Flow in Patients With Congestive Heart Failure Treated With Enalapril Stuart D. Katz, MD,* Michael Radin, MD, FACC, Thomas Graves, PHD, Cynthia Hauck, MS, Alan Block, PHD, Thierry H. LeJemtel, MD, for the Ifetroban Study Group New York, New York; Newport Beach, California; and Princeton, New Jersey OBJECTIVES BACKGROUND METHODS RESULTS CONCLUSIONS The purpose of this study was to determine the acute and chronic effects of cyclooxygenase inhibition with aspirin and thromboxane A 2 receptor blockade with ifetroban on the chronic vasodilating effects of enalapril in the skeletal muscle circulation of patients with heart failure. Angiotensin-converting enzyme inhibition and antiplatelet therapy with aspirin independently reduce the risk for subsequent nonfatal coronary events in survivors of myocardial infarction. The safety of the combined administration of angiotensin-converting enzyme inhibitors and aspirin has been questioned due to their divergent effects on the vascular synthesis of vasodilating prostaglandins. Forearm blood flow (ml/min/100 ml) at rest and during rhythmic handgrip exercise and after transient arterial occlusion was determined by strain gauge plethysmography before and 4 h and six weeks after combined administration of enalapril with either aspirin, ifetroban or placebo in a multicenter, double-blind, randomized trial of 62 patients with mild to moderate heart failure. Before randomization, forearm hemodynamics were similar in the three treatment groups except for increased resting forearm blood flow and decreased resting forearm vascular resistance in the aspirin group when compared with the placebo group. After combined administration of enalapril and study drug for 4 h and six weeks, changes from prerandomization values of mean arterial pressure, forearm blood flow and forearm vascular resistance at rest, during handgrip exercise and after transient arterial occlusion did not differ among the three treatment groups. These findings demonstrate that the vasodilating effects of enalapril in the skeletal muscle circulation of patients with heart failure are not critically dependent on prostaglandin pathways. (J Am Coll Cardiol 1999;34:170 6) 1999 by the American College of Cardiology Angiotensin-converting enzyme (ACE) inhibition and antiplatelet therapy with aspirin independently reduce the risk for subsequent nonfatal coronary events in survivors of myocardial infarction (1,2). Whereas ACE inhibitors and aspirin have been evaluated separately in clinical trials, in clinical practice these agents are often administered together to patients with heart failure due to ischemic heart disease. The safety of the coadministration of ACE inhibitors and aspirin has been questioned due to their divergent effects From the *Columbia Presbyterian Medical Center, Division of Circulatory Physiology, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York; Pacific Coast Cardiology, Newport Beach, California; Bristol Myers Squibb, Princeton, New Jersey; and Albert Einstein College of Medicine, Division of Cardiology, Department of Medicine, New York, New York. This study was supported by a research grant from Bristol Myers Squibb. Manuscript received October 13, 1998; revised manuscript received February 17, 1999, accepted March 24, on the vascular synthesis of vasodilating prostaglandins (Fig. 1) (3). The vasodilating effects of ACE inhibitors are partly attributable to the inhibition of the metabolic degradation of bradykinin, which promotes vascular synthesis of vasodilating prostaglandins (4). Aspirin is a cyclooxygenase inhibitor which dose-dependently inhibits prostaglandin synthesis in vascular tissues (5). Administration of aspirin at a dose of 350 mg attenuates the systemic vasodilating effects of acute ACE inhibition with enalapril in patients with heart failure (6). This acute hemodynamic interaction is of uncertain clinical consequence, since improvement in functional capacity in response to long-term ACE inhibition therapy is not dependent on short-term systemic hemodynamic changes, but rather is closely correlated to increased skeletal muscle blood flow during exercise (7,8). Prostaglandins are released by endothelial cells in response to shear stress and may contribute to exercise-induced hyperemia in
2 JACC Vol. 34, No. 1, 1999 July 1999:170 6 Katz et al. Aspirin Enalapril Interaction in CHF 171 Figure 1. Schematic illustration of potential interactions of angiotensin-converting enzyme (ACE) inhibitors, bradykinin and aspirin on vascular prostacyclin (PGI2) production. Whether inhibition of vascular cyclooxygenase by antiplatelet doses of aspirin attenuates bradykin-induced prostaglandin-mediated vasodilation in response to ACE inhibition is uncertain. ATII angiotensin II; stimulatory effect; inhibitory effect;? uncertain effect. the skeletal muscle circulation (9,10). Whether prostaglandins contribute to increased vasodilatory capacity in the skeletal muscle circulation during chronic ACE inhibition in patients with congestive heart failure is unknown. The current study was undertaken to determine the acute and chronic effects of cyclooxygenase inhibition with aspirin and thromboxane A 2 receptor blockade with ifetroban on the chronic vasodilating effects of enalapril in the skeletal muscle circulation of patients with heart failure. Forearm blood flow was determined at rest and during metabolic vasodilation in response to exercise and transient ischemia before and 4 h and 6 weeks after combined administration of enalapril with either aspirin, ifetroban or placebo, in a multicenter, double-blind, randomized trial. The trial was designed to test the hypothesis that aspirin, but not ifetroban or placebo, would attenuate the vasodilating effects of enalapril during chronic therapy. METHODS Study population. Sixty-two patients with stable exertional symptoms compatible with New York Heart Association class II or III heart failure for greater than three months were enrolled in the study. Patients were recruited into the study according to the following criteria: aged 21 to 80 years, left ventricular ejection fraction 0.40 (determined either by radionuclide angiography, echocardiography or ventriculography within three months of study entry), ACE inhibition therapy for 3 months and enalapril at a daily dose 10 mg for at least 4 weeks before the study and New York Heart Association functional class II or III. Stable doses of digoxin, diuretics, beta-adrenergic blocking agents and long-acting nitrates were permitted as background therapy. Criteria for exclusion from the study were: therapy with calcium channel blocking agents, ticlodipine, dipyridamole and open-label aspirin or other nonsteroidal anti-inflammatory agents, hyponatremia (serum sodium concentration 136 meq/liter), uncontrolled edema, a history of stroke or transient ischemic attack within one year, peptic ulcer disease, occult blood in a stool specimen during study screening, hematocrit 32%, history of aspirin intolerance or presence of any other known risk factor for bleeding. The study protocol was approved by the ethical review committees at each of the recruiting centers. All subjects gave written informed consent before entry into the trial. Venous occlusion plethysmography. Forearm blood flow (ml/min/100 ml of forearm volume) was determined with venous occlusion strain gauge plethysmography as previously described in detail (11). Briefly, with the arm resting comfortably 10 cm above the right atrium, a calibrated mercury-in-silastic strain gauge was placed around the widest portion of the upper third of the forearm. For each measurement, forearm venous blood flow was occluded just proximal to the elbow with the rapid inflation of a blood pressure cuff to 40 mm Hg. A wrist cuff was inflated to suprasystolic pressures 1 min before and during each measurement to exclude the hand circulation from the blood flow determination. Plethysmographic techniques were standardized across study centers and representative studies from each center were reviewed by a single investigator (S.D.K.). For determination of resting blood flow, the venous occluding cuff was inflated for 5sat15-s intervals; five plethysmographic measurements were averaged for determination of resting forearm blood flow (ml/min/100 ml). Rhythmic handgrip exercise was performed according to the protocol previously reported by Longhurst et al. (12). Subjects rhythmically squeezed a hand dynanometer in 15-s cycles which consisted of 5sofsteady handgrip pressure alternating with 10 s of rest. Exercise corresponding to 30% of a previously determined maximum voluntary contraction was performed for 3 min. Forearm blood flow was determined in the last minute of exercise during the 5-s period of each resting cycle immediately before the next handgrip contraction. Reactive hyperemia was determined after a 5-min inflation of the cuff above the elbow to suprasystolic pressure. Peak reactive hyperemia was determined as the first blood flow measurement within 5sofcuffrelease. Forearm vascular resistance was determined from the ratio of mean arterial pressure (determined by cuff method in the contralateral arm) and forearm blood flow and was expressed in arbitrary units mm Hg/ml/min/100 ml.
3 172 Katz et al. JACC Vol. 34, No. 1, 1999 Aspirin Enalapril Interaction in CHF July 1999:170 6 Drug administration. To determine the role of the prostaglandin pathway on the vasodilating action of enalapril in the skeletal muscle circulation, patients were randomly assigned to treatment with aspirin 325 mg daily, ifetroban 250 mg daily or matching placebo. A 325-mg dose of aspirin inhibits cyclooxygenase in vascular tissue and platelets, inhibits platelet aggregation and is currently the recommended dose for secondary prevention after myocardial infarction (2). Ifetroban, an investigational thromboxane A 2 receptor antagonist, is a potent long-acting inhibitor of platelet aggregation (13,14). Study protocol. The study was a multicenter, placebocontrolled, double-blind, parallel arm design trial (see Appendix for participating centers). Eligible patients meeting initial entry criteria received single-blind placebo for one to two weeks before randomization. Enalapril therapy was discontinued during single-blind placebo therapy for 72 h before determination of baseline forearm blood flow measurements on the day of randomization. Stability of the resting forearm blood flow measurement was determined before randomization. Patients with 10% variability in two consecutive resting forearm blood flow measurements (maximum three measurements) were excluded from the trial. In patients with stable resting forearm blood flow measurements, forearm blood flow was determined during rhythmic handgrip exercise and after 5 min of arterial occlusion. After completion of the prerandomization forearm blood flow measurements, subjects were randomly assigned to one of three treatment groups in a double-blind fashion: placebo q.d., acetylsalicyclic acid 325 mg q.d. or ifetroban 250 mg q.d. Enalapril 10 mg and the first dose of the assigned double-blind study drug were simultaneously administered. To determine the acute effects of study drug enalapril interaction, forearm blood flow was determined at rest, during handgrip exercise and after 5 min of arterial occlusion 4 h after the first dose of study drug and enalapril together. After completion of the acute study, patients continued their previous dose of enalapril ( 10 mg daily) and assigned study drug for six weeks. To determine the chronic effects of the study drug enalapril interaction, forearm blood flow was determined at rest, during handgrip exercise and after 5 min of arterial occlusion after six weeks of combination therapy. Background medications were held constant through the trial. Long-acting nitrate preparations were discontinued for 72 h before all blood flow measurements. Data analysis. All values are stated as means standard errors. Mean arterial pressure, forearm blood flow and forearm vascular resistance at rest, during exercise and after 5 min of arterial occlusion were compared with repeated measures analysis of variance. Correlations between measured variables of interest were determined with simple linear regression analysis. A two-tailed probability value 0.05 was considered statistically significant. The prespecified primary end point of the study was a comparison of the change in resting forearm blood Table 1. Clinical Characteristics of Study Population (Means SD) flow and resting forearm vascular resistance from prerandomization values among the three treatment groups. Secondary end points were comparisons of the changes of forearm blood flow and forearm vascular resistance from prerandomization values during rhythmic handgrip exercise and after 5 min of arterial occlusion among the three treatment groups. Twenty patients per treatment group provided 85% power to detect a clinically significant 30% change (two-sided alpha 0.05) in forearm vascular resistance, assuming a pretreatment forearm vascular resistance of 40 mm Hg/ml/min/100 ml with a standard deviation of 15 mm Hg/ml/min/100 ml. RESULTS Placebo (n 23) Aspirin (n 20) Ifetroban (n 21) Age (yr) Weight (kg) Gender (n) 17 M, 6 F 16 M, 4 F 15 M, 6 F Etiology of CHF (n) Ischemic Nonischemic LVEF Enalapril dose (mg/day) CHF congestive heart failure; F female; LVEF left ventricular ejection fraction; M male. Clinical characteristics of study population. Sixty-two patients were enrolled in the study. Five patients did not complete the trial due to clinical instability, protocol violations or technical problems with plethysmography measurements. The clinical characteristics of the 62 patients who entered the study did not differ among the three treatment groups (Table 1). The data from the 57 patients with completed forearm blood flow measurements before randomization and after 4 h and six weeks of combination therapy with enalapril and study drug are included in the analysis. Prerandomization (baseline) measurements. Before randomization resting forearm blood flow was higher and resting forearm vascular resistance was lower in patients assigned to aspirin when compared with patients assigned to placebo (both p 0.05) (Table 2). Mean arterial pressure and forearm blood flow and forearm vascular resistance during rhythmic handgrip exercise and after 5 min of arterial occlusion did not differ in the three treatment groups before randomization. Postrandomization measurements. After coadministration of enalapril and study drug, mean arterial pressure decreased from prerandomization blood pressure by 4 to 8 mm Hg after 4 h and six weeks in all three treatment groups. Changes from prerandomization blood pressure did not differ among the three treatment groups (Fig. 2). After coadministration of
4 JACC Vol. 34, No. 1, 1999 July 1999:170 6 Katz et al. Aspirin Enalapril Interaction in CHF 173 Table 2. Blood Pressure and Forearm Hemodynamics in the Three Treatment Groups (Means SEM) Before Randomization Placebo (n 19) Aspirin (n 20) Ifetroban (n 18) MAP Rest FBF * Rest FVR * 40 5 Exercise FBF Exercise FVR Postocclusion FBF Postocclusion FVR *p 0.05 vs. placebo. FBF forearm blood flow (ml/min/100 ml); FVR forearm vascular resistance (mm Hg/ml/min/100 ml); MAP mean arterial pressure (mm Hg). enalapril and study drug, small nonsignificant changes in forearm blood flow and forearm vascular resistance at rest, during rhythmic handgrip exercise and after 5 min of arterial occlusion were observed after 4 h and six weeks in all three treatment groups. Changes from prerandomization forearm blood flow and forearm vascular resistance at rest (Fig. 3), during rhythmic handgrip exercise (Fig. 4) and after 5 min of arterial occlusion (Fig. 5) after 4 h and six weeks did not differ among the three treatment groups. The changes in resting forearm vascular resistance tended to be greatest in the placebo group (p 0.20). This finding may be attributable to the greater baseline forearm vascular resistance in the placebo group. Baseline resting forearm vascular resistance correlated significantly with subsequent changes in resting forearm vascular resistance during blinded therapy (r 0.55 and r 0.72 for change in forearm vascular resistance after 4 h and six weeks, respectively, both p 0.001). Laboratory measurements. Blood urea nitrogen, serum creatinine and serum sodium did not differ among treatment groups before randomization (blood urea nitrogen 18 1, Figure 3. Changes in resting forearm blood flow (FBF, ml/min/ 100 ml, top panel) and resting forearm vascular resistance (FVR, mm Hg/ml/min/100 ml, bottom panel) from prerandomization baseline values after 4 h (black bars) and six weeks (gray bars) of combined administration of enalapril with placebo, aspirin and ifetroban. Values are expressed as means SEM. 21 3, 16 1 mg/dl, serum creatinine , , mg/dl and serum sodium , , meq/liter, in ifetroban, placebo and aspirin groups, respectively) and did not change from baseline values in any of the treatment groups during the study. Figure 2. Change from prerandomization baseline mean arterial pressure (MAP, mm Hg) after 4 h (black bars) and six weeks (gray bars) of combined administration of enalapril with placebo, aspirin and ifetroban. Values are expressed as means SEM.
5 174 Katz et al. JACC Vol. 34, No. 1, 1999 Aspirin Enalapril Interaction in CHF July 1999:170 6 Figure 4. Changes in forearm blood flow during rhythmic handgrip exercise (FBF, ml/min/100 ml, top panel) and forearm vascular resistance during rhythmic handgrip exercise (FVR, mm Hg/ml/min/100 ml, bottom panel) from prerandomization baseline values after 4 h (black bars) and six weeks (gray bars) of combined administration of enalapril with placebo, aspirin and ifetroban. Values are expressed as means SEM. Figure 5. Changes in forearm blood flow after 5 min of arterial occlusion (FBF, ml/min/100 ml, top panel) and forearm vascular resistance after 5 min of arterial occlusion (FVR, mm Hg/ml/min/ 100 ml, bottom panel) from prerandomization baseline values after 4 h (black bars) and six weeks (gray bars) of combined administration of enalapril with placebo, aspirin and ifetroban. Values are expressed as means SEM. DISCUSSION The main finding of the current study is that six weeks of therapy with aspirin, ifetroban or placebo did not alter forearm blood flow or forearm vascular resistance at rest, or during metabolic vasodilation in response to exercise or transient ischemia in patients with heart failure receiving chronic enalapril therapy. These findings demonstrate that the vasodilating effects of ACE inhibition in the skeletal muscle circulation of patients with heart failure are not critically dependent on prostaglandin pathways. Altered prostaglandin biosynthesis in heart failure. The cardiovascular actions of ACE inhibitors are mediated by reduction of the rate of synthesis of angiotensin II and reduction of the rate of metabolic degradation of bradykinin (4). Angiotensin II and bradykinin have complex mechanisms of vascular action that are partly regulated by interactions with prostaglandins. In isolated arterial preparations and cultured human endothelial cells, angiotensin II and bradykinin stimulate prostaglandin synthesis (15 17). In patients with heart failure, evaluation of the role of prostaglandins in the response to ACE inhibition is confounded by the alterations in prostaglandin metabolism related to the heart failure state. Excess production of vasodilating prostaglandins has been reported in patients with advanced heart failure and concomitant hyponatremia (18). Endothelial dysfunction in heart failure is characterized in part by evidence of increased release of vasoconstricting prostaglandins, decreased vasodilatory response to administration of exogenous arachidonic acid and decreased messenger ribonucleic acid for cyclooxygenase in aortic endothelial cells (19,20). Comparison with previous studies. The contribution of prostaglandins to the acute systemic and regional hemodynamic effects of ACE inhibition in patients with heart failure is controversial. Administration of aspirin 350 mg essentially abolished the acute systemic vasodilatory effects of enalapril 10 mg in a crossover trial of 18 patients with moderate heart failure (6). Nishimura and colleagues reported nearly complete attenuation of the acute vasodilating effects of captopril after cyclooxygenase inhibition with indomethacin in the forearm circulation of 14 patients with heart failure (21). In contrast, acute administration of 236 mg of aspirin did not attenuate the systemic blood
6 JACC Vol. 34, No. 1, 1999 July 1999:170 6 Katz et al. Aspirin Enalapril Interaction in CHF 175 pressure lowering or forearm circulation vasodilatory effects of ACE inhibition with captopril in patients with mild to moderate heart failure (22). Cyclooxygenase inhibition with indomethacin 50 mg did not alter the vasodilatory response to acute ACE inhibition in the resting forearm circulation in patients with congestive heart failure (23). The lack of effect of aspirin and ifetroban on resting forearm blood flow and forearm vascular resistance in the current study supports these latter studies. The current findings extend those of previous studies by examining both acute and chronic effects of aspirin therapy on the vasodilating effects of ACE inhibition. The vascular effects of ACE inhibitors in the skeletal muscle circulation are closely correlated with symptomatic improvement with a long time constant for both onset and offset of action (8,24 26). Forearm blood flow and vascular resistance were not expected to change at six weeks in the placebo and ifetroban treatment groups, since all patients were receiving chronic enalapril therapy before the study. Absence of change in forearm blood flow and vascular resistance at six weeks in the aspirin treatment group demonstrates that aspirin at a dosage of 325 mg/day does not attenuate the chronic vasodilating effects of enalapril in the skeletal muscle circulation. Prostaglandins and exercise hyperemia. During chronic ACE inhibition therapy, improved exercise tolerance is closely related to increased vasodilatory capacity in the exercising skeletal muscle circulation (8). The chronic vasodilatory effects of ACE inhibition in the skeletal muscle circulation during exercise may be partly attributable to the action of prostaglandins (27,28). In normal man, plasma concentrations of the stable metabolite of prostacyclin increase during exercise (29,30). Cyclooxygenase inhibition has been reported to either decrease or have no effect on exercise-induced hyperemia in the normal human forearm (30,31). Our data support the view that the prostaglandin pathway is not critical to the vasodilatory response to submaximal exercise in the forearm circulation of patients with heart failure treated with enalapril. This finding may be due to the redundancy of the metabolic vasodilatory mechanisms in the skeletal muscle circulation (32). Interpretation of study findings. A dose of 325 mg of aspirin is recommended for secondary prevention of myocardial infarction, and thus is pertinent to the question of a clinically important aspirin ACE inhibition interaction (2). This dose of aspirin is associated with near complete suppression of thromboxane A 2 synthesis in platelets, but only partial suppression of prostacyclin synthesis in vascular tissue (5). Higher or more frequent doses of aspirin, or administration of longer acting, more potent cyclooxygenase inhibitors, may have produced different effects on skeletal muscle circulation. All patients in the study were receiving chronic therapy with enalapril at the time of randomization. Accordingly, interpretation of the current findings on forearm blood flow is limited to the effects of aspirin and ifetroban on the established, chronic vasodilating action of ACE inhibitors in the skeletal muscle vasculature and may not be predictive of the effects of aspirin and ifetroban at the initiation of ACE inhibition therapy. The effect of the severity of heart failure symptoms and hyponatremia on the interaction of ACE inhibitors and aspirin cannot be determined from the current data. Whether prostaglandins contribute to the effects of chronic ACE inhibition on maximum aerobic capacity during exercise with the lower extremities in patients with congestive heart failure cannot be determined from the present study. In a previous controlled clinical trial, four weeks of aspirin therapy had no effect on maximal oxygen uptake in patients with chronic heart failure treated with enalapril (33). Conclusions. In conclusion, the current study demonstrates that the chronic vasodilating effects of ACE inhibition in the forearm circulation of patients with heart failure are not affected by concomitant administration of aspirin. These findings contrast with those of a previous report on the acute hemodynamic effects of the ACE inhibitor aspirin interaction (6) and do not support the hypothesis that aspirin therapy attenuates the long-term effects of ACE inhibition in patients with heart failure. Since a potential negative interaction between aspirin and ACE inhibitors has been reported in some retrospective analyses of post myocardial infarction trials (3,34), prospective studies are needed to determine the effects of aspirin therapy on long-term morbidity and mortality in patients with heart failure treated with ACE inhibitors. Appendix: Investigators of the Ifetroban Multicenter Study Group Principal Investigator James Arrowood, MD John Boehmer, MD Joseph Delehanty, MD Joseph Izzo, MD Stuart Katz, MD Thierry LeJemtel, MD Michael Radin, MD Satish Sharma, MD John Smith, MD Udo Thadani, MD Institution and Location Medical College of Virginia, Richmond, Virginia Hershey Medical Center, Hershey, Pennsylvania University of Rochester Medical Center, Rochester, New York Millard Fillmore Hospital, Buffalo, New York Columbia Presbyterian Medical Center, New York, New York Albert Einstein College of Medicine, Bronx, New York Heart Institute of the Desert, Rancho Mirage, California VA Medical Center, Providence, Rhode Island New England Medical Center, Boston, Massachusetts University of Oklahoma Health Science Center, Oklahoma City, Oklahoma
7 176 Katz et al. JACC Vol. 34, No. 1, 1999 Aspirin Enalapril Interaction in CHF July 1999:170 6 Reprint requests and correspondence: Dr. Stuart D. Katz, Columbia Presbyterian Medical Center, Division of Circulatory Physiology, Room MHB5-435, 177 Fort Washington Avenue, New York, New York sdk8@columbia.edu. REFERENCES 1. Cody RJ. Comparing angiotensin-converting enzyme inhibitor trial results in patients with acute myocardial infarction (review). Arch Intern Med 1994;154: Antiplatelet Trialist s Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308: Cleland JG, Bulpitt CJ, Falk RH, et al. Is aspirin safe for patients with heart failure? (review, 53 refs). Br Heart J 1995;74: Vanhoutte PM, Auch-schwelk W, Biondi ML, et al. Why are converting enzyme inhibitors vasodilators? Br J Clin Pharmacol 1989;28:95S 104S. 5. Weksler BB, Pett SB, Alonso D, et al. Differential inhibition by aspirin of vascular and platelet prostaglandin synthesis in atherosclerotic patients. N Engl J Med 1983;308: Hall D, Zeitler H, Rudolph W. Counteraction of the vadodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1994;20: Massie BM, Kramer BL, Topic N. Lack of relationship between the short-term hemodynamic effects of captopril and subsequent clinical responses. Circulation 1984;69: Mancini DM, Davis L, Wexler JP, et al. Dependence of enhanced maximal exercise performance on increased peak skeletal muscle perfusion during long-term captopril therapy in heart failure. J Am Coll Cardiol 1987;10: Koller A, Sun D, Kaley G. Role of shear stress and endothelial prostaglandins in flow- and viscosity-induced dilation of arterioles in vitro. Circ Res 1993;72: Wennmalm A. Participation of prostaglandins in the regulation of peripheral resistance. In: Oates JA, ed. Prostaglandins and the Cardiovascular System. New York: Raven Press, 1982: Greenfield ADM, Whitney RJ, Mowbray JF. Methods for the investigation of peripheral blood flow. Br Med Bull 1963;19: Longhurst J, Capone RJ, Mason DT, Zelis R. Comparison of blood flow measured by plethysmograph and flowmeter during steady state forearm exercise. Circulation 1974;49: Schumacher WA, Steinbacher TE, Youssef S, Ogletree ML. Antiplatelet activity of the long-acting thromboxane receptor antagonist BMS 180,291 in monkeys. Prostaglandins 1992;44: Ogletree ML, Harris DA, Schumacher WA, et al. Pharmacological profile of BMS 180,291: a potent orally active thromboxane A2/ prostaglandin endoperoxide receptor antagonist. J Pharmacol Exp Ther 1993;262: Gimbrone MAJ, Alexander RW. Angiotensin II stimulation of prostaglandin production in cultured human vascular endothelium. Science 1975;189: Blumberg AL, Denny SE, Marshall GR, Needleman P. Blood vessel-hormone interaction: angiotensin, bradykinin, and prostaglandins. Am J Physiol 1977;232:H Galler M, Backenroth R, Folkert VW, Schlondorff D. Effect of converting enzyme inhibitors on prostaglandin synthesis by isolate glomeruli and aortic strips from rats. J Pharmacol Exp Ther 1982;220: Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310: Katz SD, Schwarz M, Yuen J, LeJemtel TH. Impaired acetylcholinemediated vasodilation in patients with congestive heart failure. Role of endothelium-derived vasodilating and vasoconstricting factors. Circulation 1993;88: Wang J, Seyedi N, Xiao-Bin X, et al. Defective endothelium-mediated control of coronary circulation in conscious dogs after heart failure. Am J Physiol 1994;266:H Nishimura H, Kubo S, Ueyama M, et al. Peripheral hemodynamic effects of captopril in patients with congestive heart failure. Am Heart J 1989;117: van Wijngaarden J, Smit AJ, de Graeff PA, et al. Effects of acetylsalicylic acid on peripheral hemodynamics in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Cardiovasc Pharmacol 1994;23: Townend JN, Doran J, Lote CJ, Davies MK. Peripheral haemodynamic effects of inhibition of prostaglandin synthesis in congestive heart failure and interactions with captopril. Br Heart J 1995;73: Drexler H, Banhardt U, Meinertz T, et al. Contrasting peripheral short-term and long-term effects of converting enzyme inhibition in patients with congestive heart failure. A double-blind, placebocontrolled trial. Circulation 1989;79: Pflugfelder PW, Baird MG, Tonkon MJ, et al. Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators. J Am Coll Cardiol 1993;22: Zelis R, Sinoway LI, Leuenberger U, et al. Time-constant adaptations in heart failure. Eur Heart J 1991;12 Suppl C: Koller A, Kaley G. Prostaglandins mediate arteriole dilation to increased blood flow velocity in skeletal muscle microcirculation. Circ Res 1990;67: Young EW, Sparks HV. Prostaglandins and exercise hyperemia of dog skeletal muscle. Am J Physiol 1980;238:H Böger RH, Bode-Böger SM, Schröder EP, et al. Increased prostacyclin production during exercise in untrained and trained men: effect of low-dose aspirin. J Appl Physiol 1995;78: Wilson JR, Kapoor SC. Contribution of prostaglandins to exerciseinduced vasodilation in humans. Am J Physiol 1993;265:H Shoemaker JK, Naylor HL, Pozeg ZI, Hughson RL. Failure of prostaglandins to modulate the time course of blood flow during dynamic forearm exercise in humans. J Appl Physiol 1996;81: Rowell LB. Human Cardiovascular Control. New York: Oxford University Press, 1993: Baur LHB, Schipperheyn JJ, van der Laarse A, et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J 1995;73: Nguyen KN, Aursnes I, Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am J Cardiol 1997;79:115 9.
Aspirin has perhaps the broadest spectrum
AJH 1999;12:784 789 Effect of Aspirin on Blood Pressure in Hypertensive Patients Taking Enalapril or Losartan James J. Nawarskas, Raymond R. Townsend, Michael D. Cirigliano, and Sarah A. Spinler The ability
More informationData Alert #2... Bi o l o g y Work i n g Gro u p. Subject: HOPE: New validation for the importance of tissue ACE inhibition
Vascular Bi o l o g y Work i n g Gro u p c/o Medical Education Consultants, In c. 25 Sy l van Road South, We s t p o rt, CT 06880 Chairman: Carl J. Pepine, MD Professor and Chief Division of Cardiovascular
More informationASPIRIN AND VASCULAR DISEASE
ASPIRIN AND VASCULAR DISEASE SUMMARY Aspirin is an effective antiplatelet agent for patients with cardiovascular and cerebrovascular disease. Incidence of adverse effects and drug interactions increases
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationEvidence Supporting Post-MI Use of
Addressing the Gap in the Management of Patients After Acute Myocardial Infarction: How Good Is the Evidence Supporting Current Treatment Guidelines? Michael B. Fowler, MB, FRCP Beta-adrenergic blocking
More informationvasodilatation in skeletal muscle and so improve oxygen delivery to that muscle during exercise.
Br Heart J 1986; 55: 75-80 Abnormalities of the peripheral circulation and respiratory function in patients with severe heart failure A J COWLEY, K STANER, J M ROWLEY, J R HAMPTON From the Department of
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationHEART FAILURE, the most
ORIGINAL INVESTIGATION Aspirin and the Treatment of Heart Failure in the Elderly Harlan M. Krumholz, MD; Ya-Ting Chen, PhD; Martha J. Radford, MD Objectives: We sought (1) to determine how often aspirin
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00608-7 The Prognostic
More informationPlethysmographic Curve Analysis and Response to Exercise in Normal Subjects, Hypertension, and Cardiac Failure
Plethysmographic Curve Analysis and Response to Exercise in Normal Subjects, Hypertension, and Cardiac Failure Peter I. Woolfson, BSc, MBChB, MRCP, MD; Brian R. Pullan, BSc, PhD; Philip S. Lewis, BSc,
More informationORIGINAL INVESTIGATION. Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure
Toleration of High Doses of Angiotensin-Converting Enzyme Inhibitors in Patients With Chronic Heart Failure Results From the ATLAS Trial ORIGINAL INVESTIGATION Barry M. Massie, MD; Paul W. Armstrong, MD;
More informationHeart Failure. Acute. Plasma [NE] (pg/ml) 24 Hours. Chronic
Heart Failure Heart failure is the inability of the heart to deliver sufficient blood to the tissues to ensure adequate oxygen supply. Clinically it is characterized by signs of volume overload or symptoms
More informationClinical trials with cardiac selective 1 -adrenergic blockers
Comparative Effects of Carvedilol and Metoprolol on Regional Vascular Responses to Adrenergic Stimuli in Normal Subjects and Patients With Chronic Heart Failure Katarzyna Hryniewicz, MD; Ana Silvia Androne,
More informationJournal of the American College of Cardiology Vol. 35, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00602-6 Correction
More informationLXIV: DRUGS: 4. RAS BLOCKADE
LXIV: DRUGS: 4. RAS BLOCKADE ACE Inhibitors Components of RAS Actions of Angiotensin i II Indications for ACEIs Contraindications RAS blockade in hypertension RAS blockade in CAD RAS blockade in HF Limitations
More informationLOW DOSE ASPIRIN CARDIOVASCULAR DISEASE FOR PROPHYLAXIS OF FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING
LOW DOSE ASPIRIN FOR PROPHYLAXIS OF CARDIOVASCULAR DISEASE FOR BACKGROUND USE ONLY NOT TO BE USED IN DETAILING Use of Low Dose Aspirin to Treat and Prevent Cardiovascular Disease In recent decades, aspirin
More informationNQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form
Last Updated: Version 3.2 NQF-ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Information Form Measure Set: Acute Myocardial Infarction (AMI) Set Measure ID#: Performance Measure Name:
More informationBeta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center
Beta-blockers: Now what? Annemarie Thompson, MD Assistant Professor of Anesthesia and Medicine Vanderbilt University Medical Center Beta-blockers: What s known 30 Years 30 Careers Physician clarity regarding
More informationEffects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris
Br. J. clin. Pharmac. (1987), 23, 391-396 Effects of felodipine on haemodynamics and exercise capacity in patients with angina pectoris J. V. SHERIDAN, P. THOMAS, P. A. ROUTLEDGE & D. J. SHERIDAN Departments
More informationFAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION
Br. J. clin. Pharmac. (1982), 14, 187S-19lS BENEFICIAL EFFECTS OF CAPTOPRIL IN LEFT VENTRICULAR FAILURE IN PATIENTS WITH MYOCARDIAL INFARCTION J.P. BOUNHOURE, J.G. KAYANAKIS, J.M. FAUVEL & J. PUEL Departments
More informationRACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION
RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION RACIAL DIFFERENCES IN THE OUTCOME OF LEFT VENTRICULAR DYSFUNCTION DANIEL L. DRIES, M.D., M.P.H., DEREK V. EXNER, M.D., BERNARD J. GERSH,
More informationAngina Pectoris. Edward JN Ishac, Ph.D. Smith Building, Room
Angina Pectoris Edward JN Ishac, Ph.D. Smith Building, Room 742 eishac@vcu.edu 828-2127 Department of Pharmacology and Toxicology Medical College of Virginia Campus of Virginia Commonwealth University
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationA Reduction in Some Vasodilator Responses
Cardiovasc. Res., 1969, 3, 14-21. A Reduction in Some Vasodilator Responses in Free-standing Man J. G. MOSLEY" From the Department of Physiology, The Queen's University of Belfast, Northern Ireland AUTHOR'S
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationThe Study of Endothelial Function in CKD and ESRD
The Study of Endothelial Function in CKD and ESRD Endothelial Diversity in the Human Body Aird WC. Circ Res 2007 Endothelial Diversity in the Human Body The endothelium should be viewed for what it is:
More informationBalancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients
SYP.CLO-A.16.07.01 Balancing Efficacy and Safety of P2Y12 Inhibitors for ACS Patients dr. Hariadi Hariawan, Sp.PD, Sp.JP (K) TOPICS Efficacy Safety Consideration from Currently Available Antiplatelet Agents
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationControl of blood tissue blood flow. Faisal I. Mohammed, MD,PhD
Control of blood tissue blood flow Faisal I. Mohammed, MD,PhD 1 Objectives List factors that affect tissue blood flow. Describe the vasodilator and oxygen demand theories. Point out the mechanisms of autoregulation.
More informationIntravenous Inotropic Support an Overview
Intravenous Inotropic Support an Overview Shaul Atar, MD Western Galilee Medical Center, Nahariya Affiliated with the Faculty of Medicine of the Galilee, Safed, Israel INOTROPES in Acute HF (not vasopressors)
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationMeasuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D.
Measuring Quality and Performance in Treatment of Heart Failure in African-American Patients: V-HeFT and the Road to A-HeFT Peter Carson M.D. Chronology of ISDN/Hydralazine ISDN/HYD V-HeFT I BIDIL Sub-group
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationPOSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002)
POSITION STATEMENT ON ACE-INHIBITORS (Updated December 2002) Well designed, large scale, randomized double-blind, placebo-controlled trials have validated the efficacy of the ACE-inhibitor enalapril in
More informationHeart Failure and Cardiomyopathy Center, Division of Cardiology, North Shore University Hospital, Manhasset, NY
NEUROHORMONAL ANTAGONISTS IN THE POST-MI PATIENT New Evidence from the CAPRICORN Trial: The Role of Carvedilol in High-Risk, Post Myocardial Infarction Patients Jonathan D. Sackner-Bernstein, MD, FACC
More informationDemonstration of Training Effect During Chronic f-adrenergic Blockade in Patients
Demonstration of Training Effect During Chronic f-adrenergic Blockade in Patients with Coronary Artery Disease CRAIG M. PRATT, M.D., DAVID E. WELTON, M.D., WILLIAM G. SQUIRES, JR., PH.D., TIM E. KIRBY,
More informationManagement of Myocardial Infarction & Congestive Heart Failure. Dr. Dionne Dames-Rahming
Management of Myocardial Infarction & Congestive Heart Failure Dr. Dionne Dames-Rahming Myocardial Infarction Objectives of Medical Management Decrease morbidity Reduce further myocardial damage or injury
More informationEnvironmental. Vascular / Tissue. Metabolics
Global Risk Reduction--WINS Picking Mom and Dad-2016 Environmental Vascular / Tissue Metabolics Stop smoking-1b Physical activity-1b Weight control-1b Chelation therapy-3c Influenza vaccination-1b Blood
More informationINTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE
Anand IS,, 2014; Volume 3(3): 178-187 INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH AND BIO-SCIENCE EFFECT OF NEBIVOLOL AND METOPROLOL ON PLATELET ACTIVATION IN HYPERTENSIVE PATIENTS ANAND IS, PATEL
More informationStructure and organization of blood vessels
The cardiovascular system Structure of the heart The cardiac cycle Structure and organization of blood vessels What is the cardiovascular system? The heart is a double pump heart arteries arterioles veins
More informationLab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide
Lab Period: Name: Physiology Chapter 14 Blood Flow and Blood Pressure, Plus Fun Review Study Guide Main Idea: The function of the circulatory system is to maintain adequate blood flow to all tissues. Clinical
More informationMetoprolol CR/XL in Female Patients With Heart Failure
Metoprolol CR/XL in Female Patients With Heart Failure Analysis of the Experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF) Jalal K. Ghali, MD; Ileana L.
More informationHeart Failure Clinician Guide JANUARY 2018
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2018 Introduction This evidence-based guideline summary is based on the 2018 National Heart Failure Guideline.
More information1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias
1. Antihypertensive agents 2. Vasodilators & treatment of angina 3. Drugs used in heart failure 4. Drugs used in arrhythmias Only need to know drugs discussed in class At the end of this section you should
More informationSlide notes: References:
1 2 3 Cut-off values for the definition of hypertension are systolic blood pressure (SBP) 135 and/or diastolic blood pressure (DBP) 85 mmhg for home blood pressure monitoring (HBPM) and daytime ambulatory
More informationI know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists
I know the trials in heart failure but how do I manage my patient? Dosing of neurohormones antagonists Alessandro Fucili (Ferrara, IT) Massimo F Piepoli (Piacenza, IT) Clinical Case: 82 year old woman
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationCirculation. Blood Pressure and Antihypertensive Medications. Venous Return. Arterial flow. Regulation of Cardiac Output.
Circulation Blood Pressure and Antihypertensive Medications Two systems Pulmonary (low pressure) Systemic (high pressure) Aorta 120 mmhg Large arteries 110 mmhg Arterioles 40 mmhg Arteriolar capillaries
More information9/17/2015. Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14.
0 1 2 Reference: Ruschitzka F. J Hypertens 2011;29(Suppl 1):S9-14. 3 Slide notes: Large trials such as ALLHAT, LIFE and ASCOT show that the majority of patients with hypertension will require multiple
More informationAntihypertensive Agents Part-2. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Antihypertensive Agents Part-2 Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Agents that block production or action of angiotensin Angiotensin-converting
More informationJournal of the American College of Cardiology Vol. 35, No. 5, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 5, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00546-5 CLINICAL
More informationJournal of the American College of Cardiology Vol. 38, No. 5, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 5, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01571-6 Survival
More information» A new drug s trial
» A new drug s trial A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause
More informationOptimal Adrenergic Blockades in Heart Failure. Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea
Optimal Adrenergic Blockades in Heart Failure Jae-Joong Kim MD, PhD Asan Medical Center, University of Ulsan, Seoul, Korea Contents Harmful effects of adrenergic system in heart failure Clinical studies
More informationOnline Appendix (JACC )
Beta blockers in Heart Failure Collaborative Group Online Appendix (JACC013117-0413) Heart rate, heart rhythm and prognostic effect of beta-blockers in heart failure: individual-patient data meta-analysis
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationSpecial circulations, Coronary, Pulmonary. Faisal I. Mohammed, MD,PhD
Special circulations, Coronary, Pulmonary Faisal I. Mohammed, MD,PhD 1 Objectives Describe the control of blood flow to different circulations (Skeletal muscles, pulmonary and coronary) Point out special
More informationJournal of the American College of Cardiology Vol. 35, No. 4, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 35, No. 4, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00643-9 Early
More information...SELECTED ABSTRACTS...
The following abstracts, from peer-reviewed journals containing literature on vascular compliance and hypertension, were selected for their relevance to this conference and to a managed care perspective.
More informationDisclosure. Learning Objectives 1/17/2018. Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with NSAID Use
Disclosure Pumping the Breaks in Pain Management: An Update on Cardiovascular Risk with Liz Van Dril, PharmD, BCPS PGY2 Ambulatory Care Resident January 17 th, 2018 Dr. Liz Van Dril has no actual or potential
More informationCardiac evaluation for the noncardiac. Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology
Cardiac evaluation for the noncardiac patient Nathaen Weitzel MD University of Colorado Denver Dept of Anesthesiology Objectives! Review ACC / AHA guidelines as updated for 2009! Discuss new recommendations
More informationCombination of renin-angiotensinaldosterone. how to choose?
Combination of renin-angiotensinaldosterone system inhibitors how to choose? Karl Swedberg Professor of Medicine Sahlgrenska Academy University of Gothenburg karl.swedberg@gu.se Disclosures Research grants
More informationManagement of stable CAD FFR guided therapy: the new gold standard
Management of stable CAD FFR guided therapy: the new gold standard Suleiman Kharabsheh, MD Director; CCU, Telemetry and CHU Associate professor of Cardiology, Alfaisal Univ. KFHI - KFSHRC Should patients
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationAdvances in the Monitoring & Treatment of Heart Failure
Advances in the Monitoring & Treatment of Heart Failure Darrell J. Solet, MD - Cardiologist & Medical Director - Cardiovascular Institute of the South of Morgan City, Louisiana - Clinical Assistant Professor
More informationMetoprolol Succinate SelokenZOC
Metoprolol Succinate SelokenZOC Blood Pressure Control and Far Beyond Mohamed Abdel Ghany World Health Organization - Noncommunicable Diseases (NCD) Country Profiles, 2014. 1 Death Rates From Ischemic
More informationJournal of the American College of Cardiology Vol. 38, No. 1, by the American College of Cardiology ISSN /01/$20.
Journal of the American College of Cardiology Vol. 38, No. 1, 2001 2001 by the American College of Cardiology ISSN 0735-1097/01/$20.00 Published by Elsevier Science Inc. PII S0735-1097(01)01321-3 Physical
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationCardiac Output MCQ. Professor of Cardiovascular Physiology. Cairo University 2007
Cardiac Output MCQ Abdel Moniem Ibrahim Ahmed, MD Professor of Cardiovascular Physiology Cairo University 2007 90- Guided by Ohm's law when : a- Cardiac output = 5.6 L/min. b- Systolic and diastolic BP
More informationPosition Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE
Position Statement on ALDOSTERONE ANTAGONIST THERAPY IN CHRONIC HEART FAILURE Over 8,000 patients have been studied in two well-designed placebo-controlled outcome-driven clinical trials to evaluate the
More informationPCTH 400. Endothelial dysfunction and cardiovascular diseases. Blood vessel LAST LECTURE. Endothelium. High blood pressure
PCTH 400 LAST LECTURE Endothelial dysfunction and cardiovascular diseases. Classic Vascular pharmacology -chronic -systemic Local Vascular pharmacology -acute -targeted High blood pressure Blood pressure
More informationMaria Angela S. Cruz-Anacleto, MD
Maria Angela S. Cruz-Anacleto, MD 57/Female Menopausal Non-HTN, non-dm Hypothyroid (s/p RAI 1997) Levothyroxine 100 ug OD 5 Months PTA Chest discomfort Stress Echocardiography 5 Months PTA Chest discomfort
More informationCLINICAL INVESTIGATION
CLINICAL INVESTIGATION The effects of sublingually administered nitroglycerin on forearm vascular resistance in patients with heart failure and in normal subjects TSUTOMU IMAIZUMI, M.D., AKIRA TAKESHITA,
More informationHeart Failure Clinician Guide JANUARY 2016
Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Heart Failure Clinician Guide JANUARY 2016 Introduction This evidence-based guideline summary is based on the 2016 National Heart Failure Guideline.
More informationControl of blood tissue blood flow. Faisal I. Mohammed, MD,PhD
Control of blood tissue blood flow Faisal I. Mohammed, MD,PhD 1 Objectives List factors that affect tissue blood flow. Describe the vasodilator and oxygen demand theories. Point out the mechanisms of autoregulation.
More informationCHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand
CHRONIC HEART FAILURE : WHAT ELSE COULD WE OFFER TO OUR PATIENTS? Cardiac Rehabilitation Society of Thailand ENHANCED EXTERNAL COUNTER PULSATION Piyanuj Ruckpanich, MD. Cardiac Rehabilitation Center Perfect
More informationChapter 15: The Cardiovascular System
Chapter 15: The Cardiovascular System McArdle, W. D., Katch, F. I., & Katch, V. L. (2010). Exercise Physiology: Nutrition, Energy, and Human Performance (7 ed.). Baltimore, MD.: Lippincott Williams and
More informationATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular
1 ATHENA - A placebo-controlled, double-blind, parallel arm Trial to assess the efficacy of dronedarone 400 mg bid for the prevention of cardiovascular Hospitalization or death from any cause in patients
More informationIncreased forearm vascular resistance after dopamine blockade
Br. J. clin. Pharnac. (1984), 17, 373-378 Increased forearm vascular resistance after dopamine blockade D. MANNERING, E.D. BENNE7T, N. MEHTA & F. KEMP Department of Medicine 1, St George's Hospital Medical
More informationAcute Myocardial Infarction. Willis E. Godin D.O., FACC
Acute Myocardial Infarction Willis E. Godin D.O., FACC Acute Myocardial Infarction Definition: Decreased delivery of oxygen and nutrients to the myocardium Myocardial tissue necrosis causing irreparable
More informationCatheter Based Denervation for Heart Failure
Catheter Based Denervation for Heart Failure David E. Kandzari, MD, FACC, FSCAI Chief Scientific Officer Director, Interventional Cardiology Piedmont Heart Institute Atlanta, Georgia david.kandzari@piedmont.org
More informationMayo Clin Proc, March 2003, Vol 78 Role of ARBs in Treatment of Heart Failure 335 system, tissue-based RAS has long-term effects that can modify cardi
334 Concise Review for Clinicians Therapeutic Role of Angiotensin II Receptor Blockers in the Treatment of Heart Failure Concise Review for Clinicians PRERANA MANOHAR, MD, AND ILEANA L. PIÑA, MD Angiotensin
More informationConduit Artery Constriction Mediated by Low Flow
Journal of the American College of Cardiology Vol. 51, No. 20, 2008 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2008.01.049
More informationEffects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting Enzyme Inhibitors
Journal of the American College of Cardiology Vol. 40, No. 8, 2002 2002 by the American College of Cardiology Foundation ISSN 0735-1097/02/$22.00 Published by Elsevier Science Inc. PII S0735-1097(02)02304-5
More informationPROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE
Press Release Issued on behalf of Servier Date: June 6, 2012 PROCORALAN MAKING A STRONG ENTRY TO THE NEW ESC GUIDELINES FOR THE MANAGEMENT OF HEART FAILURE The new ESC guidelines for the diagnosis and
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationJournal of the American College of Cardiology Vol. 36, No. 3, by the American College of Cardiology ISSN /00/$20.
Journal of the American College of Cardiology Vol. 36, No. 3, 2000 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00 Published by Elsevier Science Inc. PII S0735-1097(00)00790-7 Acute
More informationCangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015
Cangrelor: Is it the new CHAMPION for PCI? Robert Barcelona, PharmD, BCPS Clinical Pharmacy Specialist, Cardiac Intensive Care Unit November 13, 2015 Objectives Review the pharmacology and pharmacokinetic
More informationCoronary Artery Disease: Revascularization (Teacher s Guide)
Stephanie Chan, M.D. Updated 3/15/13 2008-2013, SCVMC (40 minutes) I. Objectives Coronary Artery Disease: Revascularization (Teacher s Guide) To review the evidence on whether percutaneous coronary intervention
More information325 mg aspirin and plavix
325 mg aspirin and plavix 12-3-2006 Background Dual antiplatelet therapy with clopidogrel plus low-dose aspirin has not been studied in a broad population of patients at high risk for. Compare Aspirin
More informationRole of nitric oxide in exercise hyperaemia during prolonged rhythmic handgripping in humans
Journal of Physiology (1995), 488.1, pp.259-265 47 259 Role of nitric oxide in exercise hyperaemia during prolonged rhythmic handgripping in humans Christopher K. Dyke, David N. Proctor, Niki M. Dietz
More informationRenal Artery Stenosis: Insights from the CORAL Trial
Renal Artery Stenosis: Insights from the CORAL Trial Christopher J. Cooper, M.D., FACC, FACP Dean and Senior Vice President University of Toledo, College of Medicine President, Ohio Chapter ACC State of
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAcute Myocardial Infarction
Acute Myocardial Infarction Hafeza Shaikh, DO, FACC, RPVI Lourdes Cardiology Services Asst.Program Director, Cardiology Fellowship Associate Professor, ROWAN-SOM Acute Myocardial Infarction Definition:
More informationA Randomized Comparison of Clopidogrel and Aspirin Versus Ticlopidine and Aspirin After the Placement of Coronary Artery Stents
Journal of the American College of Cardiology Vol. 41, No. 6, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Science Inc. doi:10.1016/s0735-1097(02)02974-1
More informationJournal of the American College of Cardiology Vol. 50, No. 19, by the American College of Cardiology Foundation ISSN /07/$32.
Journal of the American College of Cardiology Vol. 50, No. 19, 2007 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2007.07.058
More information